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In pediatric neuroblastoma, MYCN-amplification correlates to poor clinical outcome and new treat-
ment options are needed for these patients. Identifying the metabolic adaptations crucial for tumor
progression may be a promising strategy to discover novel therapeutic targets. Here, we have com-
bined proteomics, gene expression profiling, functional analysis, and metabolic tracing to decipher
the impact of MYCN on neuroblastoma cell metabolism. We found that high MYCN levels are corre-
lated with altered expression of proteins involved in multiple metabolic processes, including
enhanced glycolysis and increased oxidative phosphorylation. Unexpectedly, we discovered that
MYCN-amplified cells showed de novo glutamine synthesis. Furthermore, inhibition of b-oxidation
reduced the viability of MYCN-amplified cells in vitro and decreased tumor burden in vivo, while
not affecting non-MYCN–amplified tumors. Our data provide information on metabolic processes in
MYCN expressing tumors, which could be exploited for the development of novel targeted therapies.
INTRODUCTION
Neuroblastoma (NB) is a heterogeneous childhood tumor of the sympathetic nervous system, originating
from embryonal neural crest cells (Brodeur, 2003; Cheung and Dyer, 2013).MYCN-oncogene amplification
is a strong clinical marker of aggressive disease and poor outcome and is present in40% of high-risk cases
(Maris, 2010; Peifer et al., 2015). Importantly, an overall elevated MYC signaling is also predictive of high-
risk and stage of the disease, independently from MYCN-amplification (Fredlund et al., 2008).
The MYCN transcription factor belongs to the MYC family of oncoproteins (comprising MYCN, c-MYC, and
MYCL), whose expression is deregulated in a vast number of human cancers. MYC overexpression is func-
tionally linked to most aspects of tumorigenesis (Dang, 2012; Meyer and Penn, 2008) and is involved in the
regulation of nucleotide biosynthesis, ribosome and mitochondrial biogenesis, and other metabolic pro-
cesses (Miller et al., 2012). Furthermore, MYC-regulated proliferation is associated with enhanced activity
of mitochondrial processes, and MYC inhibition decreases metabolic activity of cancer cells, leading to
reduced proliferation. In addition, it has been shown that MYC overexpressing cells use both oxidative
phosphorylation (OXPHOS) as well as glycolysis for energy production (Morrish et al., 2008).
Despite an increasing recognition of the importance of tumor metabolism for cancer aggressiveness and
progression, still very few reports exist on the metabolic properties of MYCN-amplified tumors. We have
previously shown that MYCN inhibition in MYCN-amplified neuroblastoma cells leads to accumulation
of cytoplasmic lipid droplets, a phenomenon linked to mitochondrial dysfunction and inhibition of fatty
acid oxidation (Zirath et al., 2013).
Here, we have characterized the consequences of central metabolic alterations in NB. To obtain a deeper
understanding of the role of MYCN in regulating metabolic changes in NB cells, we downregulatedMYCN
followed by an integrated analysis combining quantitative mass spectrometry proteomics (Branca et al.,
2014) with transcriptome analysis of patient datasets (Kocak et al., 2013). Metabolic properties of neuro-
blastoma cells were characterized by functional assays and metabolic tracing experiments. Our findings
show thatMYCN-amplified NB cells and tumors display prominent protein and gene expression alterations
in metabolic genes compared with non-MYCN-amplified NB, indicative of overall activated mitochondrial188 iScience 21, 188–204, November 22, 2019 ª 2019 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Protein and mRNAOverlap of Metabolism-Related Genes Display Dependence on MYC Signaling Level
Heatmap displaying proteins involved in metabolic processes (left) and mRNA levels of the corresponding genes in NB
patients (right). Red: upregulation; blue: downregulation. MYC signaling was inferred using gene expression (Fredlund
et al., 2008). Top: theMYCN-amplified (MNA) cases were separated and the remaining samples were then subdivided into
quartiles of inferred MYC signaling (Q1-4). The heatmap to the left shows changes in protein expression upon MYCN
downregulation in BE(2)shMYCN cells for 24 and 48 h, and the right heatmap shows the expression of the corresponding
genes in 612 neuroblastoma patients (Kocak et al., 2013) divided according to MYC signaling or MNA cases as indicated.
See also Figure S1.and glycolytic function and unexpectedly associated with glutamine synthesis. Furthermore, we found that
b-oxidation of fatty acids is a major contributor to mitochondrial oxidative processes.
Collectively, we have identified a promising approach to targetMYCN-amplified tumors by demonstrating
that inhibition of fatty acid oxidation led to a reduced tumor burden inMYCN-amplified xenograft models,
whereas not affecting non-MYCN-amplified tumors.RESULTS
Overlap of the Protein and mRNA Profiles of MYCN-amplified NB Cells and Tumors Shows
Dependency on the Level of MYC Signaling
To identify differentially regulatedmetabolic pathways inMYCN-amplified versus non-MYCN-amplified tu-
mor samples and establish the connection to a cell line model with adjustable MYCN levels, we combined
information from protein levels in vitro with mRNA expression from patient datasets (Kocak et al., 2013). In
order to explore how MYCN accounts for relevant metabolic processes, we performed high-resolution
mass spectrometry quantitative proteomics following MYCN downregulation (Figure S1A) (Branca et al.,
2014; Kall et al., 2007) in MYCN-amplified SK-N-BE(2) cells stably expressing a small hairpin construct
against MYCN under the control of an inducible doxycycline promoter, BE(2)sh MYCN (Henriksen et al.,
2011). MYCN levels were either high due to the MYCN-amplification in untreated cells, termed ‘‘BE(2)sh
MYCNON’’ or downregulated upon treatment with doxycycline in ‘‘BE(2)sh MYCNOFF’’ cells (Figure S1B).
In total, 6504 proteins were identified and 4779 passed initial quality controls (Figure S1C). Out of these,
1781 (37%) were significantly differentially up- or downregulated at a cutoff 1.4 and 0.7, respectively, in
the same direction at both 24 and 48 h when comparing doxycycline-treated with nontreated BE(2)sh
MYCN cells (Table S1). The proteomics findings were validated using immunoblotting (Figure S1D).
Gene Set Enrichment Analysis (GSEA) identified metabolism as one of the most affected processes in NB
cells. We asked if these differences in protein levels in vitro relate to gene expression differences in NB pa-
tients (Figure 1). To this end, we compared metabolic proteins affected by MYCN regulation with mRNA
expression data from neuroblastoma primary tumors (Kocak et al., 2013). The proteomics data show up-
(in red) and downregulated (in blue) proteins upon MYCN downregulation. Notably, we observed that
the protein expression pattern after MYCN downregulation in vitro was opposite to the mRNA expressioniScience 21, 188–204, November 22, 2019 189
levels of the corresponding genes in patients withMYCN-amplification, whereas it showed a similar pattern
to that of patients with lower MYC signaling (Figure 1 and Table S2). This highlights the adequacy of our
in vitro model system to study the impact of MYCN on metabolic processes while reflecting MYCN-asso-
ciated expression patterns in patients. These data suggest that MYCN-amplification alters key metabolic
pathways as glycolysis and gluconeogenesis, fatty acid biosynthesis, citric acid cycle, mitochondrial elec-
tron transport chain, glutathione metabolism, and redox enzymes (Figures S2–S4).MYCN Levels Are Linked to Metabolic Programs and Clinical Outcome
Analysis of gene and protein expression in BE(2)sh MYCN ON versus BE(2)sh MYCN OFF cells revealed
prominent differences in the main metabolic pathways. Combined mapping of mRNA and protein expres-
sion shows altered levels of several glycolytic enzymes (Figure S2), including hexokinase isoform 2 (HK2),
which has been previously implicated in NB (Klepinin et al., 2014). We next analyzed overall survival in
two neuroblastoma patient cohorts with similar proportions of MYCN-status and patient data covering
all five INSS stages (Figure S1E; Kocak et al., 2013; Molenaar et al., 2012). High levels ofHK2were correlated
with poor clinical outcome (Figures 2A and S1F) and we also observed that HK2 expression was related to
MYCN levels in NB tumors and cells (Figures 2B and 2C).
In addition, enzymes of the tricarboxylic acid cycle (TCA) and the electron transport chain (ETC) were also
overexpressed inMYCN-amplified cells and tumors (Figures S2 and S3). The enzymes citrate synthase (CS),
isocitrate dehydrogenase isoform 2 (IDH2), and alpha ketoglutarate dehydrogenase-like (OGDHL) were
found to have enhanced expression both at the mRNA and at the protein levels in MYCN-amplified cells
and patients (Figure S2). HighmRNA expression of the genes encoding themajority of TCA enzymes signif-
icantly correlated to poor patient survival (Figure S2). Importantly, we also demonstrated major alterations
at the protein and mRNA levels of complexes of the ETC and in the ATP synthase (Figure S3). Most of these
respiratory subunits were upregulated in MYCN-amplified cells and tumors, although some subunits were
also found to be downregulated. Notably, high expression of the MYCN-associated respiratory subunit
genes correlated to poor overall survival (Figure S3).
Gene and protein expression data showed an enhanced expression of key antioxidant-mediating enzymes in
MYCN-amplified cells and tumors (Figure S4). Among them were several enzymes of glutathione metabolism
(Figures S4A and S4B) and of glutathione-linked ROS detoxification (Figure S4C). Furthermore, members of
theperoxiredoxinROSscavenger system, includingperoxiredoxin 6 (PRDX6),wereupregulated inMYCN-ampli-
fied tumors and/or cells (Figure S4C). HighmRNAexpression levels of themajority of theMYCN-associated anti-
oxidant regulating enzymes (Figure S4C) correlated to worse prognosis and a reduced overall survival in NB pa-
tients. We investigated the impact of MYCN expression on OXPHOS in NB cells in more detail. Gene set
enrichment analysis (GSEA) of the protein profile of BE(2)sh MYCN cells demonstrated that proteins positively
regulated by MYCN were associated with aerobic respiration and mitochondrial translation processes (Fig-
ure 2D). Data analysis suggested that themajority ofmitochondrial proteins are overexpressed inMYCN-ampli-
fiedNBcells and tumors (Figure S2 andTable S1). Thegeneencoding the transcription factor nuclear respiratory
factor 1 (NRF1), which regulatesmitochondrial biogenesis through activationof keymetabolic enzymesessential
for mitochondrial translation and respiration (Huo and Scarpulla, 2001), was found upregulated inMYCN-ampli-
fied cells and correlated to reduced survival probability in neuroblastoma patients (Figure 2E and Table S1). We
used transmissionelectronmicroscopy (TEM) to show intactmitochondrial architecture inBE(2)shMYCNONand
Tet-21/NON cells, whereas reduced electron density and an increased number of damaged cristaewere found
in themitochondria of BE(2)shMYCNOFFandof Tet-21/NOFFcells (Figures 2F andS1I).Notably,MYCNdown-
regulationwas associatedwithdecreasednumber aswell as swellingofmitochondria (Figures 2F andSFI).Mem-
bers of both the mitochondrial fission as well as fusion machinery were upregulated inMYCN-amplified tumors
and/or cells (Tables S1 and S2), including optic atrophy 1 (OPA1) andmitochondrial fission process 1 (MTFP1). In
addition, highmRNAexpression levelsofOPA1andMTFP1 correlatedwithworseprognosis and reducedoverall
survival in NB patients (Figures 2G and S1J).
Although the analysis of whether the regulation of metabolic genes occurred by direct or indirect
transcriptional activity of MYCN is out of the scope of the present study, we compared the 313 metabolic
proteins from our proteomics analysis shown in Figure 1 with a list of direct MYCN targets in neuroblastoma
cell lines previously published (Hsu et al., 2016). These authors used chromatin-immunoprecipitation
(ChIP)-sequencing to identify direct MYCN target genes. We found that 45 of our proteins were present
in their list of MYCN targets and importantly, that the direction of the shMYCN regulation of these proteins190 iScience 21, 188–204, November 22, 2019
Figure 2. MYCN Levels Are Linked to Metabolic Programs and Clinical Outcome
(A) Kaplan-Meier plot showing overall survival of NB patients based on HK2 mRNA levels subdivided into expression quartiles (Q1-4).
(B) Boxplots of HK2 expression based on quartiles of MYC signaling and MYCN-amplified cases in clinical NB samples (Kocak et al., 2013; Fredlund et al.,
2008).
(C) Immunoblot showing HK2 protein expression after treatment of BE(2)sh MYCN cells with 2 mg/mL doxycycline as indicated. Representative blot from
three independent experiments is shown; a-tubulin was used as a loading control.
(D) Gene Ontology (GO) aerobic respiration and mitochondrial translation enrichment plots (using c5.bp.v5.2.symbols.gmt gene set derived from the
Biological Process Ontology) in BE(2)sh MYCN ON vs. BE(2)sh MYCN OFF NB cells. Red: upregulation; blue: downregulation.
(E) Kaplan-Meier overall survival curve from the Kocak cohort based on the mRNA expression of the NRF1 gene.
(F) Transmission electron microscopy images of representative mitochondria in BE(2)sh Scramble and BE(2)shMYCN cells. Cells were treated with vehicle or
2 mg/mL doxycycline for 72 h. Scale bars indicate 1 mm.
(G) Kaplan-Meier overall survival curves from the Kocak cohort based on the mRNA expression of the MTFP1 and OPA1 genes.
See also Figures S2–S4.was in all cases contrary to the action of MYCN (activation/repression) these authors describe for the cor-
responding genes. Thus, if MYCN activates a particular gene, we observed that shMYCN downregulated
the corresponding protein and vice versa for all of these 45 proteins (Table S3). MYCN could indirectly
modify the levels of the other proteins shown in Figure 1 through the plethora of transcriptional regulatorsiScience 21, 188–204, November 22, 2019 191
controlled by this oncoprotein (Hsu et al., 2016) or by other regulatory loops. Furthermore, additional pro-
teins affected by shMYCN could be direct MYCN-targets not identified by Hsu et al. (2016). In summary, our
data analysis suggests that MYCN increases expression of glycolytic and mitochondrial enzymes and high-
lights the importance of metabolism in mediating tumor aggressiveness in MYCN-amplified NB.
MYCN Increases the Glycolytic and OXPHOS Capacity of MYCN-amplified NB Cells
To investigate the functional impact of MYCN on metabolism in NB cells we employed extracellular flux-
based analyses. We compared the glycolytic capacity of three cell lines in which MYCN expression can
be regulated with doxycycline, BE(2)sh MYCN, Kelly shMYCN, and Tet-21/N (Figures S1B and S1H), before
and after MYCN downregulation, as well as of non-MYCN-amplified NB cells. Glycolytic parameters (basal
glycolysis, glycolysis, glycolytic capacity, and glycolytic reserve) were assessed by measuring the extracel-
lular acidification rate (ECAR) (Figure S5A). We found that all parameters were significantly reduced after
72 h of MYCN inhibition in two different MYCN-amplified NB cell lines and in the Tet-21/NMYCN-overex-
pressing NB cell line (Figures 3A and 3B). Examination of the ECAR in the non-MYCN-amplified SH-EP, SK-
N-SH, and SK-N-AS NB cell lines revealed reduced ECAR for all glycolytic parameters in comparison with
BE(2)sh MYCN cells (Figure 3A). Taken together, our results demonstrate thatMYCN-amplification is asso-
ciated with enhanced glycolytic activity in NB.
Next, we analyzed key parameters of respiration in severalMYCN-amplified and non-MYCN-amplified NB
cells by measuring the oxygen consumption rate (OCR) (Figure S5B): basal, ATP-coupled, maximal/un-
coupled respiration, as well as the spare/reserve respiration. Our analysis showed that MYCN-amplified
NB cells and MYCN-overexpressing Tet-21/N cells displayed increased OCR levels compared with non-
MYCN-amplified NB and cells with MYCN downregulation (Figures 3C and 3D). Both basal and maximal
respiration were significantly higher in BE(2)sh MYCN ON cells compared with cells after 72 h of MYCN
downregulation (BE(2)sh MYCN OFF) or non-MYCN-amplified NB cells (Figures 3C and 3D). In addition,
ATP-coupled and increased uncoupled respiration indicated that MYCN expression promotes energy pro-
duction via oxidative phosphorylation. Together, gene expression and functional assays demonstrate that
MYCN positively regulates mitochondrial respiration in MYCN-amplified NB cells.
To evaluate the ability of the cells to regulate both glycolytic flux and mitochondrial respiration as a
response to induced metabolic stress, we used the ATP synthase inhibitor oligomycin and the mitochon-
drial uncoupler FCCP, respectively (Figure 3E). Inhibition of ATP synthase forced all cell lines to increase the
glycolysis rate to compensate for the lack of mitochondrial energy production to a similar extent, indepen-
dently of theirMYCN status (Figure 3F). Uncoupling of ETC by FCCP increasedmitochondrial respiration to
maximum levels. Although all cells increased OXPHOS upon uncoupling, the elevation was significantly
higher in BE(2)sh MYCN ON cells in comparison to MYCN OFF, SH-EP, and SK-N-SH cells (Figure 3F). In
conclusion, we found that the stressed phenotype of the BE(2)sh MYCN ON cells was characterized by a
shift in the metabolic balance toward robustly increased oxidative phosphorylation as well as enhanced
aerobic glycolysis. In contrast, BE(2)sh MYCN OFF, SH-EP, and SK-N-SH cells increased glycolysis in a
similar range but were not able to generate such a strong OXPHOS stress response.
Contribution of Glucose, Glutamine, and Fatty Acids to OXPHOS
The obtained results indicated that MYCN-amplified NB cells are characterized by both enhanced glycol-
ysis and mitochondrial respiration. We next analyzed the contribution of the three crucial mitochondrial
fuels—glucose, glutamine, and fatty acids. Wemeasured OCR in the presence or absence of specific inhib-
itors of the corresponding oxidation pathways. We used UK5099, an inhibitor of themitochondrial pyruvate
transporter (MPT), to evaluate the impact of glucose on respiration, whereas the fatty acid oxidation
pathway was inhibited by etomoxir, which inhibits carnitine palmitoyltransferase 1 (CPT1C), the rate-
limiting enzyme of b-oxidation. To determinate glutamine oxidation we employed the kidney-type gluta-
minase 1 (GLS1) inhibitor BPTES. The decreased respiration in response to inhibition of the oxidation path-
ways determinates the capacity of the cells to oxidize a particular fuel. We found that approximately 65% of
the mitochondrial respiratory capacity in MYCN-amplified NB cells was dependent on fatty acid oxidation
(FAO) (Figures 4A, 4B, S5C, and S5D). Surprisingly, our results demonstrated glutamine independence of
mitochondrial respiration inMYCN-amplifiedNB cells compared with non-MYCN-amplified NB andMYCN
OFF cells (Figures 4A and 4B). Thus, our data suggest that fatty acids are an important fuel for mitochon-
drial respiration in NB cells. Indeed, mitochondrial oxidation of glutamine was significantly lower than






Figure 3. MYCN Increases the Glycolytic and OXPHOS Capacity of MYCN-amplified NB Cells
(A) Quantification of extracellular acidification rate (ECAR) in BE(2)sh MYCN ON, BE(2)sh MYCN OFF, SK-N-SH, SH-EP, and SK-N-AS cells.
(B) Quantification of ECAR levels in Kelly shMYCN and Tet-21/N cells before and after regulation of MYCN expression as indicated.
(C) Quantification of oxygen consumption rate (OCR) in BE(2)sh MYCN ON, BE(2)sh MYCN OFF, SK-N-SH, SH-EP, and SK-N-AS cells.
(D) Quantification of OCR levels in Kelly shMYCN and Tet-21/N cells before and after regulation of MYCN expression as indicated.
(E) Baseline and stressed phenotype (open and filled circles, respectively) of BE(2)shMYCN before and after downregulation of MYCN expression, SK-N-SH,
and SH-EP cells, as indicated.
(F) Visualization of the increase of metabolic potential in the experiments shown in (E).
All data are presented as the mean G SD of three independent experiments performed at 72 h of MYCN regulation, with *, **, *** indicating p < 0.05, p <
0.01 and p < 0.001, respectively.
See also Figure S5.




Figure 4. Relative Contribution of Glucose, Glutamine, and Fatty Acids to OXPHOS
(A) Quantification of OCR in BE(2)sh MYCN cells before and after downregulation of MYCN for 72 h and in SH-EP cells as
indicated. FA = fatty acids, GLC = glucose, GLN = glutamine.
(B) Quantification of OCR in Neuro-2A mouse neuroblastoma cells.
(C) WST-1 assay showing percentage of viable BE(2)sh MYCN ON and Tet-21/N ON cells after five days in substrate-
restricted medium as indicated.
(D) Number of viable SK-N-BE(2) cells during five days in substrate-limited conditions determined by cell counting at the
indicated time points.
All data are presented as mean G SD from three independent experiments, with *, **, ***, **** indicating p < 0.05,
p < 0.01, p < 0.001 and p < 0.0001, respectively.
See also Figure S5.glutamine was increased in BE(2)sh MYCN OFF cells compared with BE(2)sh MYCN ON cells. In addition,
oxidation of glutamine was also higher in SH-EP non-MYCN-amplified cells than in BE(2)sh MYCNON cells
or in Neuro-2Amouse neuroblastoma cells, and similar to the BE(2)sh MYCNOFF cells (Figures 4A and 4B).
Since glutamine is a substrate commonly oxidized in cultured cells, the low glutamine oxidation in BE(2)sh
MYCN ON NB cells was unexpected. To evaluate the impact of glucose and glutamine on cell survival we
determined the viability of MYCN-amplified NB cells upon starvation conditions. Five days of glucose
deprivation resulted in 90% reduction of viable BE(2)sh MYCN ON, SK-N-BE(2), and Tet-21/N cells. In
contrast, glutamine withdrawal alone reduced cell viability only by 30% compared with complete medium
conditions, and MYCN-amplified NB cells demonstrated glutamine independent proliferation after an
initial adaptation time (Figures 4C and 4D). Taken together, our results highlight a low glutamine oxidation
rate and only a small impact of glutamine starvation in highly proliferative MYCN-amplified NB cells.Neuroblastoma Cells Are Able to Synthesize Glutamine
As mentioned above, when we compared the ability of NB cells to oxidize glucose, glutamine and fatty
acids, we found that MYCN-amplified NB cells display reduced glutamine oxidation and the ability to sur-
vive glutamine starvation. To further investigate this phenotype, we performed isotope tracing experi-
ments with U-13C6-glucose and U-




Figure 5. MYCN-amplified NB Cells Exhibit De Novo Glutamine Synthesis Pattern
(A–D) The contribution of glucose and glutamine toward TCA-cycle metabolites was measured by metabolic tracing using U-13C6-glucose or U-
13C5-
glutamine in BE(2)sh MYCN cells as indicated. Comparison of mass isotopologue distributions (MID) of citrate (A), acetyl-CoA (B), a-ketoglutarate (C), and
glutamine (D) in BE(2)shMYCNON and in BE(2)shMYCNOFF cells after five days of MYCN downregulation with 2 mg/mL doxycycline. MI of labeled carbons
as indicated (M0-M6).
See also Figure S6.a major source of TCA cycle carbon, because U-13C6-glucose cultures exhibited 55%
13C enrichment of cit-
rate, with a prominent 13C2 mass isotopomer (Figure 5A), and 64% of acetyl-CoA, mainly as
13C2 (Figure 5B),
whereas U-13C5-glutamine gave only 4%
13C enrichment in a-ketoglutarate, mostly as 13C5 (Figure 5C).
After MYCN inhibition, the glucose contribution to citrate and acetyl-CoA diminished somewhat
(Figures 5A and 5B), whereas glutamine contribution to a-ketoglutarate and citrate increased markedly
(Figures 5A–5C), suggesting a switch toward oxidation of glutamine, presumably by activation of gluta-
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Figure 6. Fatty Acid b-oxidation in MYCN-amplified NB Cells
(A) Schematic picture showing significantly regulated mRNAs and proteins involved in b-oxidation of fatty acids, based on KEGG pathway maps. Red and
blue colors represent up- and downregulated mRNAs (ovals) in MYCN-amplified versus non-MYCN amplified tumors, or proteins (rectangles) in BE(2)sh
MYCN ON versus BE(2) sh MYCN OFF cells. The correlation of expression of different genes (high or low) to patient survival using the Oberthuer patient
dataset (Oberthuer et al., 2006) is indicated. ns= not statistically significant.
(B) Gene ontology fatty acid b-oxidation enrichment plot (using c5.bp.v5.2.symbols.gmt gene set derived from the Biological Process Ontology) in BE(2)sh
MYCN ON versus BE(2)sh MYCN OFF cells.
(C) Left graph shows quantification of basal OCR in BE(2)sh MYCN and SH-EP cells. Right graph shows quantification of maximal OCR (in response to 2 mM
FCCP) in the same cells.
All data are presented as the mean G SD of three independent experiments, with *, **, ***, **** indicating p < 0.05, p < 0.01, p < 0.001 and p < 0.0001,
respectively.MYCN OFF cells as well (Figures S6A and S6B). In both conditions, about one-third of TCA cycle carbons
were derived from an unknown (12C) source, potentially fatty acids.
We noted that most of the intracellular glutamine was not labeled from U-13C5-glutamine in BE(2)sh MYCN
ON cells, suggesting that it was not derived from uptake from the medium. Instead, we found that a ma-
jority of the cellular glutamine was synthesized from glucose via a-ketoglutarate (Figures 5C and 5D). At this
time point, the medium glutamine concentration was 1 mM, showing that this phenomenon was not due
to the exhaustion of glutamine. In contrast, in BE(2)sh MYCNOFF cells, there was almost no glutamine syn-
thesis, and instead most of the glutamine was derived from the medium (Figure 5D). Such glutamine syn-
thesis pattern is uncommon in cancer cells. To support our findings, we performed tracing experiments
with both U-13C5-glucose and U-
13C5-glutamine in two different MYCN-amplified or overexpressing cell
lines where we inhibited MYCN using the small chemical MYC/MYCN-inhibitor 10058-F4 (Muller et al.,
2014) or by doxycycline. In SK-N-BE(2) cells, we obtained 60% 13C5 glutamine, indicating that the major
part of glutamine carbons was derived from medium glutamine, but we also observed 13C2,
13C3, and
13C4
mass isotopomers (Figure S6C), suggesting glutamine synthesis from glucose. In Tet-21/N cells, most
glutamine appeared to be synthesized from glucose (Figure S6D), similar to BE(2)sh MYCN cells. In both
cell lines, MYCN inhibition prevented de novo synthesis of glutamine. The lack of glutamine synthesis in
MYCN OFF cells was likely mediated by inhibition of glutamate-ammonia ligase, because glutamate re-
mained labeled from U-13C6-glucose in BE(2)sh MYCN OFF cells (Figure S6E). In neither condition was
glutamine converted to lactate (‘‘glutaminolysis’’) (Figure S6F).
Fatty Acid b-oxidation in MYCN-amplified NB Cells
The above results show that fatty acids greatly contribute to OXPHOS inMYCN-amplified cells (Figures 4A,
4B, S5C, and S5D), and a more detailed analysis of gene and protein data confirmed that MYCN-amplifi-
cation was indeed linked to the expression of enzymes involved in FAO (Figures 6A and 6B). Specifically,
we found that high expression of the genes encoding the enzymes involved in regulating the last key steps
of FAO, including hydroxyacyl-CoA dehydrogenase (HADH), was associated with adverse outcome in neu-
roblastoma (Figure 6A).
To functionally assess the impact of MYCN expression on FAO, we measured OCR in the presence of BSA-
coupled palmitate as an exogenous source of fatty acids, and compared with unconjugated BSA as control.
Interestingly, MYCN positively regulated the capacity for FAO, because addition of palmitate resulted in a
dramatic increase in both basal andmaximal respiration rate in the BE(2)shMYCNON compared with BE(2)
sh MYCN OFF and SH-EP non-MYCN-amplified cells (Figure 6C). These results suggest that MYCN in-
creases the capacity to oxidize exogenous fatty acids. In contrast, all parameters of mitochondrial respira-
tion remained low in non-MYCN-amplified NB cells.
Inhibition of Fatty Acid b-oxidation in MYCN-amplified NB Cells Reduces Tumor Burden
Our results showed that the metabolic phenotype ofMYCN-amplified NB cells is characterized by high rates of
OXPHOS. In addition, we found that fatty acids greatly contribute to mitochondrial respiration inMYCN-ampli-
fiedNBcells.Analysisof theKocak (Kocaketal., 2013) andVersteeg (Molenaaretal., 2012)datasetsdemonstrated
a robust correlationbetweenhighexpressionof thegeneencoding the rate-limitingenzymeofFAO,CPT1C, with
poor prognosis in NB patients (Figures 7A and S7A), suggesting that CPT1 could be an attractive treatment
target. To study the effect of FAO inhibition in NB, we treated SK-N-BE(2), SH-EP, and SK-N-AS cells with two
differentCPT1 inhibitors, etomoxirand teglicar.Weobserved that theviability of SK-N-BE(2) cellswas significantly
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Figure 7. Inhibition of Fatty Acid b-oxidation Reduces Tumor Burden
(A) Kaplan-Meier overall survival curve for the Kocak cohort based on CPT1C mRNA expression quartiles (Q1–4).
(B) Percentage of viable cells as determined by WST-1 assay after seven days of etomoxir treatment in SK-N-BE(2), SH-EP, and SK-N-AS cells.
(C) Percentage of viable SK-N-BE(2) and SH-EP cells after five days of culturing in substrate-restricted medium as determined by cell counting. All data in B
and C are presented as mean G SD from three independent experiments. MNA = MYCN-amplified; NMNA = non-MYCN-amplified.
(D) Soft agar assay of SK-N-BE(2) after ten days of DMSO or 50 mM etomoxir treatment. Representative images from three independent experiments are
shown to the left. Quantification of colony size was performed using OpenCFU software, shown to the right.
(E) Immunoblot showing tyrosine hydroxylase (TH) expression after treatment of TH-MYCN tumor spheres with etomoxir as indicated. Representative blot
from three independent experiments is shown. b-actin was used as loading control.
(F) Tumor volume index (TVI) in xenograft models of SK-N-BE(2) (left panel) and SK-N-AS (right panel) NB cells. NMRI nude mice were treated daily with
vehicle (10% b-cyclodextrin) or 20 mg/kg etomoxir. SK-N-BE(2) xenograft: n = 6 for the vehicle group and n = 5 for the etomoxir group, SK-N-AS xenograft:
n = 5 for the vehicle group and n = 5 for the etomoxir group. All data are presented as mean G SD.
(G) SK-N-BE(2) xenograft tumor weights at endpoint. n = 6 for the vehicle group and n = 5 for the etomoxir group. All data are presented as mean G SD.
(H) Microscopic images of IHC staining of in vivo derived tumors labeled with anti-Ki67, anti-MYCN, and anti-HIF1a antibodies. Representative images from
six vehicle and five etomoxir treated SK-N-BE(2) xenograft tumors are shown. Scales bars indicate 50 mm.
(I) SK-N-AS xenograft tumor weights at endpoint. n = 5 for the vehicle group and n = 5 for the etomoxir group.
All data are presented as mean G SD, with *, ** indicating p < 0.05 and p < 0.01, respectively.
See also Figure S7.inhibitionofb-oxidationdidnot haveanyeffect onSH-EPorSK-N-AScells, suggesting thatMYCN-amplifiedcells
are more dependent on the FAO pathway (Figures 7B and S7B). We also found that treatment with both com-
pounds resulted in the accumulation of lipid droplets (Figure S7F) according to our previous data on etomoxir
(Zirath et al., 2013). In addition, delipidized FBS significantly reduced the number of alive SK-N-BE(2) cells
comparedwith cells in completeFBS,whereas SH-EP cells culturedunder the sameconditionswere less sensitive
to the reductionof available lipids in themedium (Figure7C). Furthermore,we founda significantdecrease in size
of soft agar colonies formed by SK-N-BE(2) cells upon etomoxir treatment (Figure 7D) and a robust reduction in
colony number by teglicar (Figure S7C). In addition, we observed that inhibition of b-oxidation in tumor spheres
derived from tumors from the TH-MYCNmouse model resulted in increased expression of the neural differenti-
ation marker tyrosine hydroxylase (TH) (Figure 7E). Together our results indicate the importance of FAO for
MYCN-amplifiedNBproliferation and survival. Next, we analyzed the therapeutic effect of FAO inhibition in vivo
using two differentMYCN-amplified NB cell lines. Nude mice were subcutaneously injected with SK-N-BE(2) or
IMR32 cells followedby etomoxir treatment. Fromday five onwards, we detected a significant decrease in tumor
volume index in the treatedmice comparedwith control animals in both experiments (Figures 7F [left panel] and
S7D). This result was verified by analysis of tumor weight at endpoint (Figure 7G). Staining of the tumors derived
from the in vivo experiment demonstrateddecreased expression ofMYCN, the proliferationmarker Ki67, as well
as themaster regulatorofhypoxia signaling,HIF1a, uponetomoxir treatment (Figure7H).Toanalyzeany selective
effect of CPT-1 inhibition onMYCN-amplified neuroblastoma tumors we next conducted an in vivo study using
non-MYCN-amplified cells. Nude mice were injected with SK-N-AS cells followed by etomoxir injection. In
contrast to the results obtained using SK-N-BE(2) and IMR32 cells, six days of etomoxir treatment did not have
any effect on tumor volume index and/or tumor weight of the SK-N-AS tumors (Figure 7F [right panel] and Fig-
ure 7I). Staining of the SK-N-AS tumors showed that etomoxir treatment did not impact expression of any of the
proteins analyzed (Figure S7G). Together, our data demonstrate that NB cells are differentially sensitive to FAO
inhibition depending on their MYCN status.DISCUSSION
During tumor progression, cancer cells need to adjust their metabolic activity in order to maintain high
biosynthetic rates needed for rapid cell growth, despite conditions of low nutrient and oxygen availability,
and these adaptations are crucial for cancer cell survival. This metabolic rewiring guarantees a rapid energy
supply in the form of ATP and a stable source of intermediary metabolites and reducing equivalents
needed for the synthesis of new biomass and the control of redox homeostasis (Deberardinis and Chandel,
2016). The relevance of metabolic alterations for tumor biology has resulted in numerous clinical trials
based on agents targeting tumor metabolism that have been initiated during the last decade (Luengo
et al., 2017). Some of them have already been approved for the treatment of specific tumor types, including
the mTOR inhibitor Everolimus for the treatment of metastatic renal cell carcinoma (Polivka and Janku,
2014). The proliferation rate of several malignances requires high glucose level and may be sensitive to in-
hibition of glucose transporters (Hay, 2016). The combination of antioxidants or ROS-modulating agents
with chemotherapy results in increased efficacy of treatment of patients with neck and head cancer (Ka-
wecki et al., 2007; Shapiro et al., 2005). However, very little is known regarding the metabolic features ofiScience 21, 188–204, November 22, 2019 199
MYCN-amplified tumors, and, specifically, neuroblastoma. Furthermore, to directly target the transcrip-
tional activity of MYC proteins continues to be a major challenge (Dang et al., 2017). Therefore, targeting
processes downstream of MYCN could represent a successful approach to inhibit MYCN-driven malig-
nancies. Understanding how MYCN alters the metabolic properties of NB could help to develop novel
therapeutic strategies. To explore possible clinical applications of targeting metabolic processes in
MYCN-amplified NB requires an accurate and detailed picture of possible metabolic aberrations. Here,
we have used the combined information from mRNA and protein expression data, placed into a biological
context when integrated with functional analysis, to depict the main metabolic features of this disease. We
show that MYCN correlates with metabolic gene and protein expression programs in NB and that MYCN
functionally affects major aspects of cell metabolism in NB cells.
Notably, the overlay between proteins and mRNAs not only revealed an overlap between in vitro and pa-
tient data but also displayed dependency on MYC signaling level. This detailed overview of the MYCN-
associated metabolic processes in NB, based on the analysis of gene and protein expression data, allowed
us to expose that MYCN-amplified cells and tumors display enhanced expression of proteins and genes
involved in glycolysis, OXPHOS, and ROS detoxification. These data provide important clues of the meta-
bolism inMYCN-amplified tumors that could be exploited for the development of therapeutic approaches.
An increased glycolytic flux is a characteristic feature of most cancers and is advantageous mainly because
it provides energy during conditions of low oxygen levels and for the generation of chemical building
blocks needed for anabolic processes used by cancer cells (Deberardinis and Chandel, 2016). Although
previous reports have suggested NB cells and tumors to highly depend on glycolysis for survival and ma-
lignancy (Levy et al., 2012; Matsushita et al., 2012), here we could demonstrate for the first time that MYCN
enhances OXPHOS in NB cells. It is generally believed that metabolic remodeling is a dynamic process that
varies depending on the stage of tumorigenesis (Deberardinis and Chandel, 2016). In this regard, although
glycolysis activation is a hallmark of many tumors, there is an increasing appreciation of the importance of
mitochondria for cancer cell survival, including the oxidation of substrates such as glucose, glutamine, and
fatty acids. In fact, under some circumstances during the tumorigenic process, neoplastic cells may be crit-
ically dependent on mitochondria and oxidative phosphorylation rather than on glycolysis (Vyas et al.,
2016). There is also evidence for tumors with the capacity to switch between glycolytic and oxidative meta-
bolism under conditions of limiting substrate accessibility, and in response to hypoxia (Deberardinis and
Chandel, 2016). As other tumorigenic events, this metabolic adaptation is likely to be a consequence of
the actions of oncogenes and tumor suppressors (Nagarajan et al., 2016).
Hereweshow thatneuroblastomacells relybothonglycolysis andOXPHOS forenergyproduction,but themeta-
bolic programdriven byMYCN-amplification seems to depend to a greater extent onOXPHOS. BothOXPHOS
capacity andglycolytic rateare significantly reduced followingMYCNdownregulation inNBcells andare lower in
non-MYCN-amplified cells compared with amplified, showing that both pathways are positively associated to
MYCN expression. However, simulation of energy demand condition demonstrates the ability ofMYCN-ampli-
fied cells to increase OXPHOS-dependent ATP production to a greater extent than non-amplified cells. On the
contrary, glycolytic parameters areMYCN independent upon stress, as bothMYCN-amplified and nonamplified
cell lines increased glycolysis to a similar extent. Of importance for possible therapeutic interventions, the anal-
ysis of patient gene expression data and proteomics results shows that high MYCN levels are associated with
elevatedexpressionof keyenzymes involved inglycolysis and the citric acidcycleandwithalterations in the levels
of respiratory chain proteins. High expression of a vast majority of the corresponding genes correlates to poor
survival of NB patients. We analyzed the impact of the expression levels of specific metabolic genes on neuro-
blastoma patient survival using the Kocak cohort (Kocak et al., 2013), one of the biggest publicly available neu-
roblastoma datasets covering gene expression data for 649 patients from all five INSS stages of the disease.We
validated the results using a second independent dataset (Molenaar et al., 2012) with a similar proportion of
MYCN-amplified and non-MYCN-amplified patients as the Kocak cohort and with patient data from the five
INSS stages. Our results suggest that targeting these enzymes or pathways could provide therapeutic opportu-
nities for neuroblastoma treatment not explored to date.
Additionally, increasing evidence show that selection of alterations that cause escape from oxidative dam-
age is an important mechanism of metabolic adaptation in tumors (Rodic and Vincent, 2018) (Helfinger and
Schroder, 2018) and has been linked to chemotherapy resistance in cancer stem cells (Diehn et al., 2009).
Among the different functional mitochondrial protein categories and gene programs in our data were200 iScience 21, 188–204, November 22, 2019
enzymes involved in ROS detoxification, including members of the peroxiredoxin system and those regu-
lating cellular GSH levels. MYCN-amplified tumors are likely to have higher energy demand due to
increased proliferation rate. Thus, they may compensate the increased ROS production due to increased
OXPHOS by upregulation of these ROS detoxication systems required for cell survival.
Fatty acids, glucose, and glutamine are crucial substrates for Krebs cycle function and mitochondrial en-
ergy production in many cancer types (Boroughs and Deberardinis, 2015). In fact, nutrient dependency
is recognized as a feature of MYC-transformed tumors (Dang, 2012). Several studies have demonstrated
glutamine addiction of cancer cells driven by MYC (Wise et al., 2008; Wise and Thompson, 2010), although
MYC is also able to induce glutamine synthesis in a mouse model of NSCLC (Yuneva et al., 2012). Here we
demonstrate that neuroblastoma cells are able to fuel oxidativemetabolism using different substrates, with
fatty acids and glucose as themajor sources, and with limited contribution of glutamine inMYCN-amplified
cells. Importantly, these cells are able to perform de novo glutamine synthesis based on metabolic tracing
experiments showing uptake of U-13C6-glucose for glutamine synthesis inMYCN-amplified cells. In spite of
glutamine being the most abundant amino acid in plasma (Smith and Wilmore, 1990), intra-tumoral avail-
ability of glutamine might be restricted due to limited vascularization and nutrient diffusion. Notably,
MYCN-amplified cells are able to survive glutamine starvation and even support cell growth after an initial
period of adaptation. Our data may explain the adaptability and high aggressiveness of MYCN-driven tu-
mors and provide new information about neuroblastoma biology.
As mentioned above, both glucose and fatty acids are the major substrates for OXPHOS in MYCN-ampli-
fied neuroblastoma cells. Previous studies have determined the feasibility of targeting glucose utilization
as a strategy to treat neuroblastoma (Aminzadeh et al., 2015). Since no previous reports have approached
the impact of lipid catabolism in neuroblastoma, here we characterized the therapeutic potential of inter-
fering with fatty acid oxidation in this tumor. Stimulation of FAO can provide a mechanism for survival in the
absence of glucose by contributing to cytosolic NADPH levels and ATP supply by OXPHOS (Bellance et al.,
2009; Carracedo et al., 2013). We found that MYCN is linked to multiple changes in the mRNA and protein
expression levels of b-oxidation–associated enzymes. Acyl-CoA dehydrogenases (ACADSs) are involved in
regulating the first step of fatty acid oxidation. Importantly, protein expression of ACADSs were found to
correlate inversely to NB patient survival, whereas those enzymes regulating the last key steps of b-oxida-
tion (3-hydroxyacyl-CoA dehydrogenases [HADH] and 3-ketoacyl thiolase [ACAA2]) correlate with poor
outcome when highly expressed (Figure 6A). High expression of gene encoding the b-oxidation rate-
limiting enzyme CPT-1 also correlates with poor prognosis in NB patients. Hence, based on these obser-
vations, the picture of a potential role of b–oxidation inMYCN-amplified NB is not clear-cut. However, our
results strongly suggest that fatty acids are amajor substrate for OXPHOS-based energymetabolism in NB.
Interestingly, we found that MYCN positively regulates the capacity for oxidizing exogenous fatty acids in
NB cells. Furthermore, we showed that reduced availability of extracellular lipids, without any chemical
intervention, diminished neuroblastoma cell viability in vitro. Together these findings reflect the overall
induced OXPHOS capacity of MYCN-amplified NB cells, which includes the ability of oxidizing fatty acids.
Accordingly, the CPT-1 small molecule inhibitors etomoxir and teglicar were able to reduceMYCN-ampli-
fied neuroblastoma cell viability and colony formation. Although etomoxir, an irreversible CPT1 inhibitor,
has been described to be able to inhibit mitochondrial complex I, this occurs at concentrations much
higher than those used in the present study (Yao et al., 2018). Etomoxir reached Phase II clinical trials as
an antidiabetic agent before being discontinued due to hepatic toxicity but continues to be widely used
as a tool to study FAO in preclinical studies. Teglicar is a recently developed selective and reversible
CPT1 inhibitor that also shows antidiabetic activity (Conti et al., 2011). This molecule does not share a
similar toxicity profile as etomoxir. While we and others have previously used etomoxir as a tool to inhibit
FAO in neuroblastoma cells in vitro (Zirath et al., 2013; Nalecz et al., 1997; Zimmermann et al., 2017), we
show here for the first time that this FAO-inhibitor is able to reduce MYCN-amplified xenograft tumor
growth in vivo. Importantly, we demonstrate that non-MYCN-amplified neuroblastoma tumor growth
was not affected by FAO-inhibition, thus showing specificity for MYCN-amplification. In this respect it is
intersting that b-oxidation of exogenous fatty acids delivered by nearby adipocytes to ovarian cancer cells
was shown to be an important mechanism for tumor metastasis and rapid tumor growth (Nieman et al.,
2011). The outcome of our in vivo study demonstrated the therapeutic potential of FAO inhibition in
MYCN-amplified NB and suggests that this approach may be used as a basis for the development of novel
therapeutic strategies for MYCN-amplified NB patients.iScience 21, 188–204, November 22, 2019 201
Together our data indicate that MYCN facilitates a high-energetic metabolic phenotype in NB, pointing to
the possibility that tumors with elevated MYCN signaling have a greater ability than the nonamplified tu-
mors to use different metabolic strategies during tumor progression, depending on microenvironmental
and intratumoral nutrient availability and level of metabolic stresses (Jose et al., 2011). Our work highlights
several pathways as critical for the aggressive clinical behavior of MYCN-amplified NB tumors. This infor-
mation can be used to further investigate the importance of these regulatory metabolic networks for
MYCN-amplified NB cell survival and as a basis for the development of novel therapies.
Limitations of the Study
In this study, we performed in vitro experiments using the CPT1C inhibitors etomoxir and teglicar, whereas
the in vivo experiments were limited to etomoxir. As mentioned in the discussion, etomoxir was discontin-
ued from clinical trials due to toxicity and has, at higher concentrations than we employed, unspecific tar-
gets such as complex I of the electron transport chain. Future in vivo studies with additional CPT1C inhib-
itors, including teglicar, remain to be performed. Notably, the neuroblastoma cell lines used in our
xenograft experiments are highly aggressive and develop tumors rapidly, allowing for a very short thera-
peutic window of only 7–8 days. Therefore, it may be of importance to use the transgenic TH-MYCNmouse
neuroblastoma model in future experiments.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.10.020.
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Figure S1. Related to Figure 1 and Figure 2. Outline of proteomics experiments, validation of 
downregulation of MYCN following doxycycline treatment and patient survival analysis. (A) Schematic 
workflow of the high-resolution quantitative proteomics approach. (B) Immunoblot showing MYCN expression 
after treatment of BE(2)sh MYCN cells with 2 µg/mL doxycycline (dox) for the indicated time points. 
Representative blot from three independent experiments is shown. (C) Unsupervised clustering of proteins 
passing initial quality control at 24 and 48 h compared to non-treated BE(2)sh MYCN cells. (D) Immunoblot 
analysis of selected proteins indicated up- or downregulated in the proteomic data after 24 h of MYCN 
downregulation. Representative blots from two or three independent experiments are shown. a-Tubulin was 
used as loading control. (E) Summary of the proportion of patients belonging to each INSS stage and MYCN-
amplification status in the two patient datasets used for survival analyses in this study (Kocak et al., 2013 
(Molenaar et al., 2012)). (F) Kaplan-Meier plot showing overall survival of neuroblastoma patients based on 
HK2 mRNA levels subdivided into expression quartiles (Q1-4). Data from the Versteeg dataset (Molenaar et 
al., 2012). (G) Scheme summarizing the origin of the MYCN-overexpressing Tet-21/N cell line from a sub-
clone of the non-MYCN-amplified SK-N-SH cell line, adapted from (Thiele, 1998). (H) Immunoblot showing 
MYCN expression after treatment of Kelly shMYCN and Tet-21/N cells with 2 µg/mL doxycycline (dox) for 
the indicated time points. The blot shown is representative from three independent experiments. (I) 
Transmission electron microscopy images of representative mitochondria in Tet-21/N cells. Cells were 
treated with vehicle or 2 µg/mL doxycycline for 72 h, as indicated. Scale bars represent 1 µm. (J) Kaplan-
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Figure S2. Related to Figure 2. MYCN-regulated mRNA and protein expression alterations of central 
metabolic pathways. Schematic picture showing significantly regulated mRNAs and proteins of the 
glycolysis/gluconeogenesis, TCA cycle and fatty acid biosynthesis pathways, based on Kyoto Encyclopedia 
of Genes and Genomes (KEGG) pathway maps (www.genome.jp/kegg/). Red and blue colors represent, up- 
or downregulated mRNAs (ovals) in MYCN-amplified versus non-MYCN amplified tumors, or proteins 
(rectangles) in BE(2)sh MYCN ON versus BE(2) sh MYCN OFF cells. The correlation of expression of 
different genes (high or low) to patient survival using the Oberthuer patient dataset (Oberthuer et al., 2006) 
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Figure S3. Related to Figure 2. MYCN-regulated mRNA and protein expression alterations of the 
respiratory chain. Schematic picture showing significantly regulated mRNAs and proteins of the respiratory 
chain, based on KEGG pathway maps. Red and blue colors represent, up- or downregulated mRNAs (ovals) 
in MYCN-amplified versus non-MYCN amplified tumors, or proteins (rectangles) in BE(2)sh MYCN ON versus 
BE(2) sh MYCN OFF cells. The correlation of expression of different genes (high or low) to patient survival 
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Figure S4. Related to Figure 2. MYCN regulated mRNA and protein expression of antioxidant 
detoxification pathways. (A) Schematic picture showing significantly regulated mRNAs and proteins 
involved in glutathione metabolism, based on KEGG pathway maps. Red and blue colors represent, up- or 
downregulated mRNAs (ovals) in MYCN-amplified versus non-MYCN amplified tumors, or proteins 
(rectangles) in BE(2)sh MYCN ON versus BE(2) sh MYCN OFF cells. The correlation of expression of 
different genes (high or low) to patient survival using the Oberthuer patient dataset (Oberthuer et al., 2006) 
is indicated. ns= not statistically significant. (B) KEGG glutathione metabolism enrichment plot (using 
c2.cp.kegg.v5.2.symbols.gmt gene set obtained from the KEGG pathway database) in BE(2)sh MYCN ON 
versus BE(2)sh MYCN OFF cells. (C) List of enzymes involved in antioxidant scavenger pathways. Symbols 
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Figure S5. Related to Figure 3 and Figure 4. Effect of MYCN downregulation on glycolysis and 
respiration in MYCN-amplified NB cells. (A) Illustration of the principle of the Glycolysis Stress assay 
(adapted from Agilent Seahorse XF technology). Extracellular Acidification Rate (ECAR) was measured using 
a Seahorse Extracellular Flux Analyzer XFe96. Glycolysis is defined by the ECAR measured after addition of 
10 mM glucose minus the basal ECAR. Glycolytic capacity is the maximal ECAR measured in response to 
addition of 1 µM oligomycin (ATP synthase inhibitor) minus the non-glycolytic acidification. The difference 
between glycolytic capacity and glycolysis is defined as the glycolytic reserve. (B) Illustration of the principle 
of the XF Cell Mito Stress assay (adapted from Agilent Seahorse XF technology). ATP production is defined 
as the difference between the basal OCR and the OCR after addition of 1 µM oligomycin. The maximal 
respiration consists of the OCR measured in response to addition of 2 µM FCCP. The reserve capacity is the 
difference between maximal respiration and basal OCR. (C) Quantification of OCR in BE(2)sh MYCN ON 
cells, the same data as used in Figure 4A. (D) Quantification of OCR in Kelly shMYCN and Tet-21/N cells as 
indicated. FA = fatty acids, GLC = glucose, GLN = glutamine. All data is presented as the mean ± SD of three 

































































































































































Figure S6. Related to Figure 5. Distribution of TCA metabolites. (A-D) The contribution of glucose and 
glutamine towards TCA-cycle metabolites was measured by metabolic tracing using U-13C6-glucose and U-
13C5-glutamine. Comparison of mass isotopologue distributions (MID) of aconitate (A), malate (B), glutamine 
(C, D), glutamate (E), and lactate (F). The carbon tracing was performed in BE(2)sh MYCN ON, BE(2)sh 
MYCN OFF, Tet-21/N ON, Tet-21/N OFF, and SK-N-BE(2) cells after five days of MYCN inhibition by 
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Figure S7. Related to Figure 7. Inhibition of fatty acid β-oxidation reduces tumor burden. (A) Kaplan-
Meier overall survival curve from the Versteeg cohort based on CPT1C mRNA expression. (B) Percentage 
of viable cells as determined by WST-1 assay after seven days of teglicar treatment at the indicated 
concentrations in SK-N-BE(2) and SK-N-AS cells. (C) Soft agar assay of SK-N-BE(2) after ten days of vehicle 
(H2O) or 50 µM teglicar treatment. Representative images from three independent experiments are shown to 
the left. Quantification of colony number was performed using OpenCFU software, shown to the right. (D) 
Tumor volume index (TVI) in xenograft models of IMR32 NB cells. NMRI nude mice were treated daily with 
vehicle (10 % β-cyclodextrin) or 20 mg/kg etomoxir. n = 3 for the vehicle (10 % β-cyclodextrin) group and n 
= 4 for the etomoxir group. All data is presented as mean ± SD. (E) Immunoblot showing c-MYC and MYCN 
expression in SK-N-AS NB cells. Representative blot from three independent experiments is shown. β-actin 
was used as loading control. (F) Microscopic images of ORO staining of SK-N-BE(2) and SK-N-AS cells 
treated with vehicle (DMSO) or 50 µM etomoxir or teglicar. Representative images are shown. (G) 
Microscopic images of IHC staining of in vivo derived SK-N-AS tumors labelled with anti-Ki67, anti-c-MYC, 
and anti-HIF1α antibodies. Representative images from five vehicle treated and five etomoxir treated SK-N-
AS-xenograft tumors are shown. Scale bars represent 100 µm.  
































































CONTACT FOR REAGENT AND RESOURCE SHARING  
Further information and requests for resources and reagents should be directed to and will be fulfilled 
by Lead Contact, Marie Arsenian Henriksson (marie.arsenian.henriksson@ki.se). 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Animal studies 
Five-week-old female NMRI-Foxn1nu mice purchased from Taconic Biosciences were housed, treated, 
and analyzed in accordance with the ethical permit number N71/15 approved by the Swedish ethical 
committee “Stockholms Norra Djurförsöksetiska Nämnd”. Mice were housed in specific pathogen free 
conditions where light, temperature (21°C), and relative humidity (50-60 %) were controlled. Food and 
water were available ad libitum. For xenograft experiments, 10 x 106 SK-N-BE(2), IMR32, or SK-N-AS 
cells were injected subcutaneously into the right flanks of mice. Tumor growth was monitored daily by 
caliper measurement of two dimensions. The tumor volume 0.1 cm3 was defined as tumor take point 
and animals were randomized into the treatment groups. The mice received vehicle (10 % 2-
(hydroxypropyl)-β-cyclodextrin in H2O, referred to as β-cyclodextrin) or 20 mg/kg etomoxir by i.p. 
injection daily. The animals were euthanized after six to eight days of treatment or after tumors reached 
1 cm3. The procedures for performing all animal experiments were in accordance with the principles and 
guidelines of Karolinska Institutet and the Swedish law. 
TH-MYCN tumor spheres  
For generation of TH-MYCN-derived spheres, tumors from homozygous mice, both male and female, 
were cut into small pieces and mechanically dissociated. The resulting cell suspension was washed with 
PBS twice and filtered through a 70 μm nylon membrane. To remove blood cells, the cell suspensions 
were treated with red blood lysis buffer (Sigma), followed by a PBS wash. For proliferation, cells were 
plated at a density of 5 x 105 cells/cm2 on non-coated or non-adherent tissue culture flasks (Gao et al., 
2014; (Ribeiro et al., 2016). 
Cell culture 
The human MYCN-amplified NB cell lines SK-N-BE(2) (from male origin), BE(2)sh MYCN, Kelly 
shMYCN (from female origin), expressing a doxycycline inducible MYCN shRNA, BE(2)sh Scramble, 
Tet-21/N (from female origin) overexpressing a doxycycline repressible MYCN gene (FS1G) and non-
MYCN-amplified NB cell lines SK-N-SH (from female origin), SH-EP (from female origin), SK-N-AS (from 
female origin) as well as the mouse neuroblastoma Neuro-2A cells (from male origin) were grown in 
MEME:Nutrient Mixture F-12 (1:1) medium containing 1 % non-essential amino acids (NEAA), 1 % 
GlutaMAX (Gibco) and 1 % penicillin-streptomycin. Human MYCN-amplified IMR32 cells (from male 
origin) were grown in low glucose DMEM supplemented as described above. For small hairpin (sh)-
transduced cell lines, the cell culture medium was supplemented with 10 % tetracycline-approved FBS 
(Clontech), all other cells were grown in regular 10 % FBS (Clontech) (Henriksen et al., 2011). Cell 
culture media, antibiotics and cell culture supplements were obtained from Sigma-Aldrich. Delipidized 
fetal bovine serum was from Pan Biotech. Doxycycline and the small molecule MYCN-inhibitor 10058-
F4 were from Sigma-Aldrich.  
METHOD DETAILS  
Protein extraction, digestion and iTRAQ labelling of peptides  
BE(2)sh MYCN cells treated with vehicle or 2 µg/mL doxycycline for 24 or 48 h were lysed in 4 % SDS, 
25 mM HEPES, and 1 mM DTT. Cell lysates were heated to 95°C for 5 min followed by sonication for 1 
min and centrifugation at 14 x 103 g for 15 min, discarding the pellet. Protein concentration was 
quantified using the DC protein assay (BioRad Laboratories, Hercules, CA, USA). Equal aliquots (100 
μg) of total protein lysates were mixed with 1 mM DTT, 8 M urea, 25 mM HEPES, pH 7.6 and transferred 
to a centrifugation filtering unit, 10 kDa cutoff (Microcon YM-10, Millipore), and centrifuged for 15 min, 
14 x 103 g, followed by addition of 8 M urea with 1 mM DTT  buffer and centrifuged for 15 min at 14 x 
103 g. Proteins were alkylated with 50 mM indole acetic acid in 8 M urea, 25 mM HEPES for 10 min, 
centrifuged for 15 min, 14 x 103 g, followed by two cycles of resuspension in 4 M urea, 25 mM HEPES 
and centrifugation for 15 min at 14 x 103 g. Trypsin (modified sequencing grade, Promega, Madison, 
WI, USA) (1:50, trypsin:protein) in 250 mM urea, 50 mM HEPES was added to cell lysates and incubated 
overnight at 37°C. Filter units with 10 kDa cutoff (Microcon YM-10, Millipore) were centrifuged for 15 
min, 14 x 103 g, followed by another centrifugation with Milli-Q H2O and the flow-through was collected. 
Labeling with iTRAQ (Applied Biosystems, Foster City, CA, USA) was performed according to 
manufacturer’s instructions. Briefly, each iTRAQ reagent was incubated with the protein digest for 2 h, 
pooled and acidified with formic acid. Excess reagent and detergents were removed from the pooled 
samples using a SCX-cartridge (strata-X-C, Phenomenex, Torrence, CA, USA). iTRAQ labelled 
peptides were separated by IPG-IEF on a pH 3.7-4.9 strip. 
IPG-IEF of peptides  
400 µg of iTRAQ labeled tryptic peptides were dissolved in 8 M urea. Narrow range IPG-strips for 
isoelectric focusing (pH 3.5–4.9 24 cm long) were kindly supplied by GE Healthcare Bio-Sciences AB, 
Uppsala, Sweden. Application gels were rehydrated overnight in 8 M urea and 1 % Pharmalyte 2.5–5 
(GE Health-care Bio-Sciences AB). Isoelectric focusing was performed on an Ettan IPGphor (GE 
Healthcare Bio-Sciences AB) with a 75 μA limit per strip until 100 kVh had been reached. Peptides were 
extracted by a prototype liquid handling robot, supplied by GE Healthcare Bio-Sciences AB, dried in 
Speedvac and dissolved in 3 % acetonitrile (ACN), 0.1 % formic acid (FA).   
Liquid chromatography coupled to tandem mass spectrometry (nano LC-MS/MS)  
Peptides were separated using an Agilent 1200 nano-LC system. Samples were trapped on Zorbax 
300SB-C18, 5 μm, 5 x 0.3 mm and separated on a NTCC-360/100-5-153 (Nikkyo Technos., Ltd) column 
using a gradient of A (3 % ACN, 0.1 % FA) and B (95 % ACN, 0.1 % FA), ranging from 3 % to 40 % B 
in 90 min with a flow of 0.4 μl/min. The LTQ Orbitrap Velos was operated in data dependent mode, 
selecting 5 precursors for sequential fragmentation by CID and HCD, and analyzed by the linear ion trap 
and orbitrap, respectively. Survey scan was performed in the orbitrap at 30 x 103 resolutions from 300-
2.000 m/z, using lock mass at m/z 445.120025, with a max injection time of 500 ms and AGC set to 1 x 
106 ions. For generation of HCD fragmentation spectra, a max ion injection time of 500 ms and AGC of 
5 x 104 were used before fragmentation at 37.5 % normalized collision energy (NCE), 30 ms activation 
time. For FTMS MSn spectra, normal mass range was used, centroiding the data at 7.500 resolution. 
Peptides for CID were accumulated for a max ion injection time of 200 ms and AGC of 3 x 104, 
fragmented with 35 % collision energy, wideband activation on, activation q 0.25, activation time 10 ms 
before analysis at normal scan rate and mass range in the linear ion trap. Precursors were isolated with 
a width of 2 m/z and put on the exclusion list for 60 s. Single and unassigned charge states were rejected 
from precursor selection. 
Peptide and protein identification  
Proteome Discoverer 1.3 (Thermo Scientific) using the SEQUEST search engine and Percolator (Kall 
et al., 2007) was used for protein identification. Precursor mass tolerance was set to 10 ppm and for 
fragments 0.8 Da and 0.02 Da were used for detection in the linear ion trap and the orbitrap, respectively. 
Oxidized methionine and phosphorylation on S, T and Y was set as dynamic modifications, and 
carbamidomethylation, N-terminal 8plex iTRAQ, as fixed modifications. Spectra were matched to 
Ensembl 68, limited to human protein sequences, and results were filtered to 1 % FDR. 
Liquid Chromatography – High Resolution Mass Spectrometry (LH-HRMS) 
After 5 days of MYCN inhibition with 2 µg/mL doxycycline, metabolite extracts were analyzed by liquid 
chromatography – high resolution mass spectrometry (LC-HRMS) on a Thermo Ultimate 3000 UHPLC 
system coupled to a Q-Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific, San Jose, CA, 
USA). Metabolites chromatographic separation was performed in a Merck-Sequant ZIC-HILIC column 
(150 x 4.6 mm, 5µm particle size) fitted with a Merck Sequant ZIC-HILIC guard column (20 x 2.1 mm) 
using a gradient elution of 0.1 % formic acid in water (solvent A) and ACN (solvent B). The gradient 
elution started at 20 % of solvent A and increased up to 80 % in 17 min. Then this percentage was 
maintained during 4 min. The flow rate was set at 400 µL min-1 and the column temperature and sample 
tray were held at 23°C and 4°C, respectively. 
The Ultimate UHPLC system was coupled to a Q-Exactive instrument (Thermo Fisher Scientific, 
Bremen, Germany) equipped with a heated electrospray (H-ESI II) ionization source. Nitrogen (purity > 
99,995 %) was used as sheath gas and auxiliary gas at flow rates of 45 and 10 a.u. (arbitrary units), 
respectively. The ion transfer tube was set at 320°C, the vaporizer temperature at 350°C and the 
electrospray voltage was set at 4 kV in positive mode and -3.5 kV in negative mode. A scanning rate of 
2 spectrum s-1 with a mass range of m/z 75 – 800 with a mass resolving power of 70 000 Full Width Half 
Maximum (FWHM) (m/z 200) was used. 
Full instrument calibration was performed using a MSCAL5 ProteoMassT LTQ/FT-Hybrid ESI Pos/Neg 
(Sigma-Aldrich). External mass axis calibration without the use of the specific lock masses was 
employed. The Xcalibur software version 2.2 (Thermo Fisher Scientific) was used to control the LC-MS 
system. 
The identity of metabolites was confirmed by matching retention times against those of pure chemical 
standards and accurate masses (<5 ppm). Additionally, the metabolite identities were supported by 
comparing the observed isotopomers to those expected given the isotope tracers used. 
Western Blot Analysis 
10 µg of total protein extract per sample was separated on a 4-12 % SDS-PAGE gel (Bolt Bis-Tris Plus, 
Invitrogen) and transferred to a nitrocellulose membrane using BioRad Trans-blot turbo. After blocking 
with non-fat milk, the membranes were probed with the following antibodies: mouse anti-α-Tubulin 
(Santa Cruz DM1A), mouse anti-MYCN (Santa Cruz B8.4.B), mouse anti-c-MYC (Santa Cruz sc-40), 
rabbit anti-HK2 (Atlas Antibodies HPA028587), rabbit anti-SCG2 (Atlas Antibodies HPA011893), rabbit 
anti-COX5B (Atlas Antibodies HPA034517), rabbit anti-NPM1 (Atlas Antibodies HPA011384), rabbit 
anti-RPL27 (Atlas Antibodies HPA002649), mouse anti-TH (Abcam ab112) and mouse anti-β-Actin 
(Santa Cruz C4), followed by anti-mouse or anti-rabbit HRP-conjugated secondary antibodies (DAKO). 
Bands were detected using ECLTM Western Blotting Detection Reagents (GE Healthcare).  
Transmission electron microscopy 
The pellets containing approximately 2 x 106 cells were fixed in 2.5 % glutaraldehyde in 0.1 M phosphate 
buffer at room temperature for 30 min. The sections were analyzed using a Tecnai 12 Spirit Bio TWIN 
transmission electron microscope at 100 kV as previously described (Zirath et al., 2013). 
Extracellular flux assay 
Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) were measured using an 
XFe96 Analyzer (Seahorse Bioscience, Agilent Technologies, North Billerica, MA, US) according to the 
manufacturer's instructions. Cells were plated at 0.8-1 x 104 cells/well on 96-well plates (Seahorse cell 
culture micro plates) in standard cell culture medium. After 72 h culture medium was exchanged for XF 
assay medium (Seahorse Bioscience, Billerica, MD), pH 7.4, at 37°C in a CO2-free incubator for 1 h 
before the assay. OCR and ECAR values were reported in pmol/min and mpH/min, respectively. The 
baseline levels were normalized to protein contents measured by DC protein assay (Biorad) in the XF 
plates after the experiments were terminated.  
Soft agar assay 
Assay was performed as previously described (Dzieran et al., 2018). The base layer containing 0.6 % 
SeaPlaque agarose (Cambrex BioScience-Rockland) in 1x growth medium (from 10x DMEM/F12; 
Sigma) supplemented with 10 % FBS, 1 % Penicillin/Streptomycin, 0.5 % Glutamax, 1 % non-essential 
amino acids, was added to the wells of a 12-well plate and allowed to solidify. 1 x 104 SK-N-BE(2) cells 
of a single-cell suspension in 0.4 % SeaPlaque agarose/growth medium were seeded on top of the base 
layer and, after solidification, covered by growth medium. The agarose-cell suspension and the growth 
medium were supplemented with 50 μM etomoxir or 50 µM teglicar (Sigma Aldrich Co. LCC) or with 
vehicle (H2O). The medium on top of the soft agar layers was changed every third day. After 10 to 14 
days, the living cells were stained by adding 200 μl 5 mg/mL 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT; Sigma Aldrich co. LCC) to the medium and pictures were taken using the 
ChemiDoc XRS+ System (Bio-Rad Laboratories Inc.). The size and number of colonies were quantified 
with the OpenCFU software (Geissmann, 2013). 
 
 
Immunohistochemistry analysis of tumor sections 
For immunohistochemistry (IHC) on SK-N-BE(2) and SK-N-AS xenograft tumors, transverse sections (5 
μm thick) from paraffin-embedded tissue were stained with the EnVision Gl2 Doublestain System (Dako) 
according to the manufacturer’s instructions. Briefly, paraffin was removed and samples were re-
hydrated by consecutive xylol-alcohol gradients. Sample blocking was followed by overnight incubation 
at +4°C with the following primary antibodies diluted in blocking solution: rabbit anti-Ki67 (1:250, Abcam 
ab16667), mouse anti-MYCN (1:200, Santa Cruz sc-56729), rabbit anti c-MYC (1:250, Santa Cruz sc-
789) or rabbit anti-HIF1a (1:250, Novus NB100-479). Samples were incubated with secondary antibody 
for 20 min, followed by 3-5 min incubation with DAB working solution. Nuclear staining with hematoxylin 
was performed for 2 min. Samples were dehydrated by consecutive alcohol-xylol gradients and mounted 
with Roti-histokitt mounting medium (Roth).  
Determination of cell viability 
For WST-1 viability assay, cells were seeded in 96 well plates and treated as indicated. 10 µl of WST-1 
(Roche) were added per well and after 1 h incubation, absorbance at 480 nm was measured in a 
LUMIstar Omega plate reader (BMG Labtech). For cell growth curves and cell viability determined by 
cell counting, cells where seeded in 24 well plates and after the indicated treatments and incubation 
times, cells were trypsinized, mixed with Trypan Blue (Sigma) and counted in a hemocytometer chamber 
under an inverted microscope. 
Oil Red O (ORO) staining of lipids 
Staining was performed as described previously (Zirath et al., 2013). Briefly, cells grown on coverslips 
were fixed in 4 % (w/v) paraformaldehyde before staining with 0.3 % Oil Red O (Sigma) in 60 % (v/v) 
isopropanol. For visualization, bright-field images were captured using an Axiovert 40 CFL inverted 
fluorescence microscope (Zeiss) and Axiovision Rel. 4.8 software. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Gene set enrichment 
The protein profile was analyzed using Gene Set Enrichment Analysis (GSEA), 
(http://software.broadinstitute.org/gsea/index.jsp). Differently expressed proteins (see above) were 
compared to each of the terms in Gene Ontology. Neuroblastoma patient dataset (Kocak et al., 2013) 
was analyzed using the R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl). 
Statistical analysis 
In the proteomics data, the mean of the duplicate values for controls were used to calculate ratios to 
doxycycline treated samples. Value replicates were filtered based on the ratios between the biological 
duplicates, by removing proteins outside of 2.17 SD. Proteins were considered to have changed levels 
compared to control if both of the replicates were > 2.17 standard deviations (97 % confidence, cutoffs 
1.4- and 0.7-fold). Metabolic measurements and cell viability assays were analyzed by Student’s t-test. 
Results of the in vivo experiment were analyzed using a two-way ANOVA followed by Sidak's multiple 
comparison tests. All data is presented as mean ± standard deviation (SD) with *, **, ***, **** indicating 
p<0.05, p<0.01, p<0.001 and p<0.0001, respectively. 
Gene Expression Analysis 
The expression patterns of the differentially expressed proteins in BE (2)sh MYCN ON versus BE(2) sh 
MYCN OFF cells were compared to mRNA expression data using a publicly available clinical 
neuroblastoma data set (Kocak et al., 2013) (GSE45547; NCBI Gene Expression Omnibus), conformed 
by 649 patients. Data set had complete clinical patient data, including MYCN-amplification status, with 
the exception of 37 samples. In an exploratory data clustering analysis, these 37 samples also showed 
a clear outlier expression pattern and they were subsequently excluded from further analyses. 
Normalized data was downloaded from respective data repositories and array probes were matched to 
gene symbols. Gene expression for multiple probes mapping to the same gene symbol was merged 
based on average expression on a per sample basis, followed by log2 transformation and gene-wise 
mean centering. Data was clustered based on Pearson correlation and Ward’s method. MYC pathway 
activity scores were calculated as previously described (Fredlund et al., 2008), with the minor 
modification that scores were scaled from 0 to 10 in order to enable a fair visual comparison between 
tumor samples.  
Analysis of patient data  
For survival and correlation analyses, two neuroblastoma patient data sets with RNA sequencing 
expression data from 649 (Kocak et al., 2013) or 88 (Molenaar et al., 2012) patients were used. Clinical 
and expression data of the genes of interest were extracted from the R2platform 
(https://hgserver1.amc.nl/) and analyzed using Excel and GraphPad Prism softwares. 
 
DATA AND SOFTWARE AVAILABILITY 
The accession number for the proteomics data reported in this paper is ProteomeXchange: PXD015755. 
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